Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies.
The efficacy of ganciclovir, given prophylactically, to prevent cytomegalovirus-related disease was evaluated in liver transplant recipients, mostly seropositive, under treatment with OKT3 monoclonal antibodies. The incidence of cytomegalovirus disease and visceral involvement was reduced, respectively, from 52 and 36% in the control group to 12 and 8% in the ganciclovir-treated patients. Leukopenia was a frequent (32%) side effect of ganciclovir administration.
Lumbreras
C
C
Infectious Diseases Unit, Hospital Doce de Octubre, Madrid, Spain.
Otero
J R
JR
Herrero
J A
JA
Gomez
R
R
Lizasoain
M
M
Aguado
J M
JM
Colina
F
F
Garcia
I
I
Moreno
E
E
Noriega
A R
AR
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D016031:Liver Transplantation / Q000276:immunology; D008297:Male; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D015774:Ganciclovir